Drugs /

f-18 16 alpha-fluoroestradiol

Back to Drugs List

Overview

NCI Definition [1]:
A radiopharmaceutical consisting of an estradiol analogue radiolabeled with the positron-emitting isotope fluorine F 18. F-18 16 alpha-fluoroestradiol is actively taken up in tumor cells expressing the estrogen receptor (ER), allowing visualization of ER-positive tumor cells with positron emission tomography (PET). Uptake of this agent depends upon the ER status of target tissues.

Clinical Trials

View Clinical Trials for f-18 16 alpha-fluoroestradiol

F-18 16 alpha-fluoroestradiol has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating f-18 16 alpha-fluoroestradiol, 1 is phase 2 (1 open).

ER Positive, HER2 Deficient Expression, and HER2 Negative are the most frequent biomarker inclusion criteria for f-18 16 alpha-fluoroestradiol clinical trials.

Breast carcinoma is the most common disease being investigated in f-18 16 alpha-fluoroestradiol clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating F-18 16 Alpha-Fluoroestradiol
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating f-18 16 alpha-fluoroestradiol and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
16 alpha-fluroestradiol-17 beta, f-18 fes, fes, fluoroestradiol f-18, fluoroestradiol f-18, f-18 16 alpha-fluoroestradiol, fluorine-18 16 alpha-fluoroestradiol, fluorine-18 16 alpha-fluoroestradiol
NCIT ID [1]:
C62541

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.